nodes	percent_of_prediction	percent_of_DWPC	metapath
Anagrelide—PDE3A—Dyphylline—asthma	0.254	0.35	CbGbCtD
Anagrelide—PDE3A—Aminophylline—asthma	0.193	0.265	CbGbCtD
Anagrelide—PDE3A—Theophylline—asthma	0.181	0.249	CbGbCtD
Anagrelide—CYP1A2—Zileuton—asthma	0.03	0.0413	CbGbCtD
Anagrelide—CYP1A2—Zafirlukast—asthma	0.0264	0.0364	CbGbCtD
Anagrelide—CYP1A2—Aminophylline—asthma	0.0217	0.0299	CbGbCtD
Anagrelide—CYP1A2—Theophylline—asthma	0.0204	0.0281	CbGbCtD
Anagrelide—PDE3A—Signaling by GPCR—PMCH—asthma	0.000124	0.00381	CbGpPWpGaD
Anagrelide—CYP1A2—Phase 1 - Functionalization of compounds—ALDH2—asthma	0.000123	0.00378	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CSF2RB—asthma	0.000121	0.00373	CbGpPWpGaD
Anagrelide—CYP1A2—Tryptophan metabolism—CAT—asthma	0.00012	0.0037	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—TACR2—asthma	0.000119	0.00365	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CCR8—asthma	0.000119	0.00365	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—GATA3—asthma	0.000116	0.00359	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CCL17—asthma	0.000116	0.00358	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PDE4A—asthma	0.000114	0.00352	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—IL5—asthma	0.00011	0.0034	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—CYSLTR1—asthma	0.000107	0.00329	CbGpPWpGaD
Anagrelide—CYP1A2—Arachidonic acid metabolism—PLA2G4A—asthma	0.000106	0.00327	CbGpPWpGaD
Anagrelide—CYP1A2—Phase II conjugation—GSTT1—asthma	0.000106	0.00326	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—NOS1—asthma	0.000104	0.0032	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PDE4A—asthma	0.000104	0.00319	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—VIP—asthma	0.000103	0.00318	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—UTS2—asthma	0.000103	0.00318	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—C5AR1—asthma	0.000103	0.00318	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—IL3—asthma	0.000103	0.00316	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—CCR4—asthma	9.9e-05	0.00305	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CYSLTR1—asthma	9.71e-05	0.00299	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—KNG1—asthma	9.68e-05	0.00298	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—IL2RB—asthma	9.53e-05	0.00293	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—CDK2—asthma	9.46e-05	0.00291	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PDE4D—asthma	9.44e-05	0.00291	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—C5AR1—asthma	9.37e-05	0.00289	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—UTS2—asthma	9.37e-05	0.00289	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—VIP—asthma	9.37e-05	0.00289	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CCL11—asthma	9.37e-05	0.00289	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—FCER2—asthma	9.24e-05	0.00285	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—C3AR1—asthma	9.24e-05	0.00285	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—C5—asthma	9.2e-05	0.00283	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PDE4B—asthma	9.2e-05	0.00283	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—TACR1—asthma	9.2e-05	0.00283	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CCR4—asthma	8.99e-05	0.00277	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CYSLTR2—asthma	8.9e-05	0.00274	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—IL2RB—asthma	8.65e-05	0.00267	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—ITPR1—asthma	8.64e-05	0.00266	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCL22—asthma	8.59e-05	0.00265	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—LTB4R—asthma	8.59e-05	0.00265	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PTGDR—asthma	8.59e-05	0.00265	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PDE4D—asthma	8.57e-05	0.00264	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—CCR3—asthma	8.41e-05	0.00259	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—C5—asthma	8.35e-05	0.00257	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—TACR1—asthma	8.35e-05	0.00257	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PDE4B—asthma	8.35e-05	0.00257	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—NPY—asthma	8.2e-05	0.00253	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PLA2G4A—asthma	8.07e-05	0.00249	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—CSF2—asthma	7.98e-05	0.00246	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—AGTR2—asthma	7.91e-05	0.00244	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CCR3—asthma	7.64e-05	0.00235	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—EDNRB—asthma	7.58e-05	0.00233	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—NPS—asthma	7.5e-05	0.00231	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—TAC1—asthma	7.5e-05	0.00231	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—NPY—asthma	7.45e-05	0.00229	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PPP2CA—asthma	7.43e-05	0.00229	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—CXCR3—asthma	7.36e-05	0.00227	CbGpPWpGaD
Anagrelide—CYP1A2—Phase II conjugation—GSTP1—asthma	7.34e-05	0.00226	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PMCH—asthma	7.31e-05	0.00225	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PTGDR2—asthma	7.31e-05	0.00225	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—HRH4—asthma	7.31e-05	0.00225	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NPSR1—asthma	7.31e-05	0.00225	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—IL2RA—asthma	7.19e-05	0.00222	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—AGTR2—asthma	7.18e-05	0.00221	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CSF2RB—asthma	7.15e-05	0.0022	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCR8—asthma	7.01e-05	0.00216	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TACR2—asthma	7.01e-05	0.00216	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—IL5—asthma	6.97e-05	0.00215	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PDGFB—asthma	6.94e-05	0.00214	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—EDNRB—asthma	6.88e-05	0.00212	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCL17—asthma	6.87e-05	0.00212	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—NPS—asthma	6.81e-05	0.0021	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—TAC1—asthma	6.81e-05	0.0021	CbGpPWpGaD
Anagrelide—CYP1A2—Phase II conjugation—GSTM1—asthma	6.74e-05	0.00208	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—CDK2—asthma	6.73e-05	0.00207	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PLAU—asthma	6.73e-05	0.00207	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—BDKRB2—asthma	6.73e-05	0.00207	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CXCR3—asthma	6.68e-05	0.00206	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—asthma	6.66e-05	0.00205	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—ALDH2—asthma	6.51e-05	0.00201	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—ADCY2—asthma	6.51e-05	0.00201	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—IL3—asthma	6.49e-05	0.002	CbGpPWpGaD
Anagrelide—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—asthma	6.48e-05	0.00199	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—asthma	6.39e-05	0.00197	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—IL5—asthma	6.33e-05	0.00195	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—FN1—asthma	6.26e-05	0.00193	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—GSTT1—asthma	6.19e-05	0.00191	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—NOS2—asthma	6.19e-05	0.00191	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—KIF3A—asthma	6.12e-05	0.00189	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PDE4A—asthma	6.12e-05	0.00189	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—KNG1—asthma	6.12e-05	0.00189	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—BDKRB2—asthma	6.11e-05	0.00188	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—AGTR1—asthma	6.08e-05	0.00187	CbGpPWpGaD
Anagrelide—CYP1A2—Arachidonic acid metabolism—PTGS2—asthma	5.98e-05	0.00184	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—CXCL10—asthma	5.95e-05	0.00183	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—asthma	5.94e-05	0.00183	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—asthma	5.92e-05	0.00182	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—ADCY2—asthma	5.91e-05	0.00182	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—LTC4S—asthma	5.91e-05	0.00182	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—IL3—asthma	5.89e-05	0.00181	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—ADRB2—asthma	5.77e-05	0.00178	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CYSLTR1—asthma	5.73e-05	0.00177	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—KNG1—asthma	5.56e-05	0.00171	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CMA1—asthma	5.54e-05	0.00171	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—C5AR1—asthma	5.54e-05	0.00171	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—UTS2—asthma	5.54e-05	0.00171	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCL11—asthma	5.54e-05	0.00171	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—VIP—asthma	5.54e-05	0.00171	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—AGTR1—asthma	5.52e-05	0.0017	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—ITPR1—asthma	5.46e-05	0.00168	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CXCL10—asthma	5.4e-05	0.00166	CbGpPWpGaD
Anagrelide—Ill-defined disorder—Triamcinolone—asthma	5.33e-05	0.000222	CcSEcCtD
Anagrelide—Ill-defined disorder—Methylprednisolone—asthma	5.32e-05	0.000221	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—CCR4—asthma	5.31e-05	0.00164	CbGpPWpGaD
Anagrelide—Alopecia—Betamethasone—asthma	5.29e-05	0.00022	CcSEcCtD
Anagrelide—Alopecia—Dexamethasone—asthma	5.29e-05	0.00022	CcSEcCtD
Anagrelide—Convulsion—Hydrocortisone—asthma	5.29e-05	0.00022	CcSEcCtD
Anagrelide—Nausea—Salbutamol—asthma	5.28e-05	0.00022	CcSEcCtD
Anagrelide—Hypertension—Hydrocortisone—asthma	5.27e-05	0.000219	CcSEcCtD
Anagrelide—Discomfort—Prednisolone—asthma	5.26e-05	0.000219	CcSEcCtD
Anagrelide—CYP1A2—Phase 1 - Functionalization of compounds—POMC—asthma	5.25e-05	0.00162	CbGpPWpGaD
Anagrelide—Haemoglobin—Prednisone—asthma	5.24e-05	0.000218	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—ADRB2—asthma	5.24e-05	0.00161	CbGpPWpGaD
Anagrelide—Haemorrhage—Prednisone—asthma	5.22e-05	0.000217	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—SERPINE1—asthma	5.21e-05	0.0016	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—STAT6—asthma	5.21e-05	0.0016	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—ALB—asthma	5.2e-05	0.0016	CbGpPWpGaD
Anagrelide—Myalgia—Hydrocortisone—asthma	5.2e-05	0.000216	CcSEcCtD
Anagrelide—Malaise—Triamcinolone—asthma	5.18e-05	0.000216	CcSEcCtD
Anagrelide—Malaise—Methylprednisolone—asthma	5.17e-05	0.000215	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—asthma	5.16e-05	0.000215	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—EDN1—asthma	5.16e-05	0.00159	CbGpPWpGaD
Anagrelide—Syncope—Triamcinolone—asthma	5.15e-05	0.000214	CcSEcCtD
Anagrelide—Syncope—Methylprednisolone—asthma	5.14e-05	0.000214	CcSEcCtD
Anagrelide—Discomfort—Hydrocortisone—asthma	5.14e-05	0.000213	CcSEcCtD
Anagrelide—Connective tissue disorder—Prednisone—asthma	5.13e-05	0.000213	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—LTA4H—asthma	5.12e-05	0.00158	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—CCL5—asthma	5.12e-05	0.00158	CbGpPWpGaD
Anagrelide—Nausea—Budesonide—asthma	5.12e-05	0.000213	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—IL2RB—asthma	5.11e-05	0.00157	CbGpPWpGaD
Anagrelide—Oedema—Prednisolone—asthma	5.1e-05	0.000212	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—PDE4D—asthma	5.06e-05	0.00156	CbGpPWpGaD
Anagrelide—Loss of consciousness—Triamcinolone—asthma	5.05e-05	0.00021	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—CSF2—asthma	5.04e-05	0.00155	CbGpPWpGaD
Anagrelide—Loss of consciousness—Methylprednisolone—asthma	5.04e-05	0.00021	CcSEcCtD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—asthma	5.03e-05	0.00155	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—RHOA—asthma	5.02e-05	0.00155	CbGpPWpGaD
Anagrelide—Shock—Prednisolone—asthma	5.02e-05	0.000209	CcSEcCtD
Anagrelide—Cough—Triamcinolone—asthma	5.02e-05	0.000209	CcSEcCtD
Anagrelide—Oedema—Hydrocortisone—asthma	4.98e-05	0.000207	CcSEcCtD
Anagrelide—Convulsion—Triamcinolone—asthma	4.98e-05	0.000207	CcSEcCtD
Anagrelide—Tachycardia—Prednisolone—asthma	4.98e-05	0.000207	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—NOS3—asthma	4.97e-05	0.00153	CbGpPWpGaD
Anagrelide—Convulsion—Methylprednisolone—asthma	4.97e-05	0.000207	CcSEcCtD
Anagrelide—Hypertension—Triamcinolone—asthma	4.96e-05	0.000206	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—ITPR1—asthma	4.96e-05	0.00153	CbGpPWpGaD
Anagrelide—Hypertension—Methylprednisolone—asthma	4.95e-05	0.000206	CcSEcCtD
Anagrelide—Infection—Hydrocortisone—asthma	4.95e-05	0.000206	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—TACR1—asthma	4.94e-05	0.00152	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—C5—asthma	4.94e-05	0.00152	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PDE4B—asthma	4.94e-05	0.00152	CbGpPWpGaD
Anagrelide—Hyperhidrosis—Prednisolone—asthma	4.93e-05	0.000205	CcSEcCtD
Anagrelide—Shock—Hydrocortisone—asthma	4.9e-05	0.000204	CcSEcCtD
Anagrelide—Myalgia—Triamcinolone—asthma	4.89e-05	0.000203	CcSEcCtD
Anagrelide—Nervous system disorder—Hydrocortisone—asthma	4.89e-05	0.000203	CcSEcCtD
Anagrelide—Arthralgia—Methylprednisolone—asthma	4.88e-05	0.000203	CcSEcCtD
Anagrelide—Myalgia—Methylprednisolone—asthma	4.88e-05	0.000203	CcSEcCtD
Anagrelide—Eye disorder—Prednisone—asthma	4.88e-05	0.000203	CcSEcCtD
Anagrelide—Tachycardia—Hydrocortisone—asthma	4.86e-05	0.000202	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—asthma	4.85e-05	0.000202	CcSEcCtD
Anagrelide—Skin disorder—Hydrocortisone—asthma	4.84e-05	0.000201	CcSEcCtD
Anagrelide—Ill-defined disorder—Betamethasone—asthma	4.84e-05	0.000201	CcSEcCtD
Anagrelide—Ill-defined disorder—Dexamethasone—asthma	4.84e-05	0.000201	CcSEcCtD
Anagrelide—Discomfort—Triamcinolone—asthma	4.84e-05	0.000201	CcSEcCtD
Anagrelide—Discomfort—Methylprednisolone—asthma	4.82e-05	0.000201	CcSEcCtD
Anagrelide—Hyperhidrosis—Hydrocortisone—asthma	4.82e-05	0.0002	CcSEcCtD
Anagrelide—Dry mouth—Triamcinolone—asthma	4.79e-05	0.000199	CcSEcCtD
Anagrelide—Anorexia—Hydrocortisone—asthma	4.75e-05	0.000197	CcSEcCtD
Anagrelide—Confusional state—Methylprednisolone—asthma	4.72e-05	0.000196	CcSEcCtD
Anagrelide—Malaise—Betamethasone—asthma	4.7e-05	0.000196	CcSEcCtD
Anagrelide—Malaise—Dexamethasone—asthma	4.7e-05	0.000196	CcSEcCtD
Anagrelide—Oedema—Triamcinolone—asthma	4.69e-05	0.000195	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—EDN1—asthma	4.68e-05	0.00144	CbGpPWpGaD
Anagrelide—Syncope—Dexamethasone—asthma	4.68e-05	0.000194	CcSEcCtD
Anagrelide—Syncope—Betamethasone—asthma	4.68e-05	0.000194	CcSEcCtD
Anagrelide—Arrhythmia—Prednisone—asthma	4.66e-05	0.000194	CcSEcCtD
Anagrelide—Infection—Triamcinolone—asthma	4.66e-05	0.000194	CcSEcCtD
Anagrelide—Hypotension—Hydrocortisone—asthma	4.66e-05	0.000194	CcSEcCtD
Anagrelide—Infection—Methylprednisolone—asthma	4.65e-05	0.000193	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—CCL5—asthma	4.65e-05	0.00143	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PLA2G4A—asthma	4.63e-05	0.00143	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—asthma	4.62e-05	0.00142	CbGpPWpGaD
Anagrelide—Shock—Triamcinolone—asthma	4.62e-05	0.000192	CcSEcCtD
Anagrelide—Insomnia—Prednisolone—asthma	4.61e-05	0.000192	CcSEcCtD
Anagrelide—Alopecia—Prednisone—asthma	4.61e-05	0.000192	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—CCR5—asthma	4.61e-05	0.00142	CbGpPWpGaD
Anagrelide—Shock—Methylprednisolone—asthma	4.61e-05	0.000191	CcSEcCtD
Anagrelide—Nervous system disorder—Methylprednisolone—asthma	4.59e-05	0.000191	CcSEcCtD
Anagrelide—Loss of consciousness—Dexamethasone—asthma	4.58e-05	0.000191	CcSEcCtD
Anagrelide—Loss of consciousness—Betamethasone—asthma	4.58e-05	0.000191	CcSEcCtD
Anagrelide—Paraesthesia—Prednisolone—asthma	4.58e-05	0.00019	CcSEcCtD
Anagrelide—Tachycardia—Triamcinolone—asthma	4.58e-05	0.00019	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—CSF2—asthma	4.58e-05	0.00141	CbGpPWpGaD
Anagrelide—Tachycardia—Methylprednisolone—asthma	4.57e-05	0.00019	CcSEcCtD
Anagrelide—Skin disorder—Methylprednisolone—asthma	4.55e-05	0.000189	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—IL2RA—asthma	4.54e-05	0.0014	CbGpPWpGaD
Anagrelide—Malnutrition—Prednisone—asthma	4.54e-05	0.000189	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Hydrocortisone—asthma	4.54e-05	0.000189	CcSEcCtD
Anagrelide—Hyperhidrosis—Triamcinolone—asthma	4.54e-05	0.000189	CcSEcCtD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—asthma	4.53e-05	0.0014	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—asthma	4.53e-05	0.0014	CbGpPWpGaD
Anagrelide—Hyperhidrosis—Methylprednisolone—asthma	4.53e-05	0.000188	CcSEcCtD
Anagrelide—Convulsion—Dexamethasone—asthma	4.52e-05	0.000188	CcSEcCtD
Anagrelide—Convulsion—Betamethasone—asthma	4.52e-05	0.000188	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—CCR3—asthma	4.51e-05	0.00139	CbGpPWpGaD
Anagrelide—Insomnia—Hydrocortisone—asthma	4.51e-05	0.000187	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—C3—asthma	4.51e-05	0.00139	CbGpPWpGaD
Anagrelide—Hypertension—Dexamethasone—asthma	4.5e-05	0.000187	CcSEcCtD
Anagrelide—Hypertension—Betamethasone—asthma	4.5e-05	0.000187	CcSEcCtD
Anagrelide—Paraesthesia—Hydrocortisone—asthma	4.47e-05	0.000186	CcSEcCtD
Anagrelide—Myalgia—Dexamethasone—asthma	4.44e-05	0.000185	CcSEcCtD
Anagrelide—Myalgia—Betamethasone—asthma	4.44e-05	0.000185	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—NPY—asthma	4.4e-05	0.00136	CbGpPWpGaD
Anagrelide—Discomfort—Betamethasone—asthma	4.39e-05	0.000182	CcSEcCtD
Anagrelide—Discomfort—Dexamethasone—asthma	4.39e-05	0.000182	CcSEcCtD
Anagrelide—Dyspepsia—Hydrocortisone—asthma	4.39e-05	0.000182	CcSEcCtD
Anagrelide—Hypotension—Methylprednisolone—asthma	4.37e-05	0.000182	CcSEcCtD
Anagrelide—Pain—Prednisolone—asthma	4.36e-05	0.000181	CcSEcCtD
Anagrelide—Decreased appetite—Hydrocortisone—asthma	4.33e-05	0.00018	CcSEcCtD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—asthma	4.31e-05	0.00133	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—asthma	4.31e-05	0.00133	CbGpPWpGaD
Anagrelide—Gastrointestinal disorder—Hydrocortisone—asthma	4.3e-05	0.000179	CcSEcCtD
Anagrelide—Fatigue—Hydrocortisone—asthma	4.3e-05	0.000179	CcSEcCtD
Anagrelide—CYP1A2—Biological oxidations—GSTP1—asthma	4.29e-05	0.00132	CbGpPWpGaD
Anagrelide—Vision blurred—Prednisone—asthma	4.28e-05	0.000178	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Triamcinolone—asthma	4.27e-05	0.000178	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Methylprednisolone—asthma	4.26e-05	0.000177	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—PPP2CA—asthma	4.26e-05	0.00131	CbGpPWpGaD
Anagrelide—Pain—Hydrocortisone—asthma	4.26e-05	0.000177	CcSEcCtD
Anagrelide—Oedema—Betamethasone—asthma	4.26e-05	0.000177	CcSEcCtD
Anagrelide—Oedema—Dexamethasone—asthma	4.26e-05	0.000177	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—AGTR2—asthma	4.24e-05	0.00131	CbGpPWpGaD
Anagrelide—Insomnia—Triamcinolone—asthma	4.24e-05	0.000176	CcSEcCtD
Anagrelide—CYP1A2—Metapathway biotransformation—GSTP1—asthma	4.23e-05	0.0013	CbGpPWpGaD
Anagrelide—Insomnia—Methylprednisolone—asthma	4.23e-05	0.000176	CcSEcCtD
Anagrelide—Infection—Dexamethasone—asthma	4.23e-05	0.000176	CcSEcCtD
Anagrelide—Infection—Betamethasone—asthma	4.23e-05	0.000176	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—IL2—asthma	4.22e-05	0.0013	CbGpPWpGaD
Anagrelide—Ill-defined disorder—Prednisone—asthma	4.21e-05	0.000175	CcSEcCtD
Anagrelide—Paraesthesia—Triamcinolone—asthma	4.21e-05	0.000175	CcSEcCtD
Anagrelide—Feeling abnormal—Prednisolone—asthma	4.2e-05	0.000175	CcSEcCtD
Anagrelide—Paraesthesia—Methylprednisolone—asthma	4.2e-05	0.000175	CcSEcCtD
Anagrelide—Anaemia—Prednisone—asthma	4.2e-05	0.000175	CcSEcCtD
Anagrelide—Shock—Dexamethasone—asthma	4.19e-05	0.000174	CcSEcCtD
Anagrelide—Shock—Betamethasone—asthma	4.19e-05	0.000174	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—CCR5—asthma	4.19e-05	0.00129	CbGpPWpGaD
Anagrelide—Dyspnoea—Triamcinolone—asthma	4.18e-05	0.000174	CcSEcCtD
Anagrelide—Nervous system disorder—Betamethasone—asthma	4.17e-05	0.000174	CcSEcCtD
Anagrelide—Nervous system disorder—Dexamethasone—asthma	4.17e-05	0.000174	CcSEcCtD
Anagrelide—Thrombocytopenia—Dexamethasone—asthma	4.17e-05	0.000173	CcSEcCtD
Anagrelide—Thrombocytopenia—Betamethasone—asthma	4.17e-05	0.000173	CcSEcCtD
Anagrelide—Tachycardia—Betamethasone—asthma	4.15e-05	0.000173	CcSEcCtD
Anagrelide—Tachycardia—Dexamethasone—asthma	4.15e-05	0.000173	CcSEcCtD
Anagrelide—Dyspepsia—Triamcinolone—asthma	4.13e-05	0.000172	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—IL2RA—asthma	4.13e-05	0.00127	CbGpPWpGaD
Anagrelide—Dyspepsia—Methylprednisolone—asthma	4.12e-05	0.000171	CcSEcCtD
Anagrelide—Hyperhidrosis—Dexamethasone—asthma	4.12e-05	0.000171	CcSEcCtD
Anagrelide—Hyperhidrosis—Betamethasone—asthma	4.12e-05	0.000171	CcSEcCtD
Anagrelide—Feeling abnormal—Hydrocortisone—asthma	4.11e-05	0.000171	CcSEcCtD
Anagrelide—Malaise—Prednisone—asthma	4.1e-05	0.00017	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—C3—asthma	4.09e-05	0.00126	CbGpPWpGaD
Anagrelide—Gastrointestinal pain—Hydrocortisone—asthma	4.07e-05	0.000169	CcSEcCtD
Anagrelide—Syncope—Prednisone—asthma	4.07e-05	0.000169	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—EDNRB—asthma	4.06e-05	0.00125	CbGpPWpGaD
Anagrelide—Anorexia—Betamethasone—asthma	4.06e-05	0.000169	CcSEcCtD
Anagrelide—Anorexia—Dexamethasone—asthma	4.06e-05	0.000169	CcSEcCtD
Anagrelide—Urticaria—Prednisolone—asthma	4.05e-05	0.000168	CcSEcCtD
Anagrelide—Fatigue—Triamcinolone—asthma	4.04e-05	0.000168	CcSEcCtD
Anagrelide—Fatigue—Methylprednisolone—asthma	4.04e-05	0.000168	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—NPS—asthma	4.02e-05	0.00124	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TAC1—asthma	4.02e-05	0.00124	CbGpPWpGaD
Anagrelide—Pain—Triamcinolone—asthma	4.01e-05	0.000167	CcSEcCtD
Anagrelide—Loss of consciousness—Prednisone—asthma	3.99e-05	0.000166	CcSEcCtD
Anagrelide—Hypotension—Dexamethasone—asthma	3.98e-05	0.000165	CcSEcCtD
Anagrelide—Hypotension—Betamethasone—asthma	3.98e-05	0.000165	CcSEcCtD
Anagrelide—Urticaria—Hydrocortisone—asthma	3.96e-05	0.000165	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—CXCR3—asthma	3.95e-05	0.00122	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—GSTM1—asthma	3.95e-05	0.00122	CbGpPWpGaD
Anagrelide—Body temperature increased—Hydrocortisone—asthma	3.94e-05	0.000164	CcSEcCtD
Anagrelide—Abdominal pain—Hydrocortisone—asthma	3.94e-05	0.000164	CcSEcCtD
Anagrelide—Convulsion—Prednisone—asthma	3.94e-05	0.000164	CcSEcCtD
Anagrelide—Hypertension—Prednisone—asthma	3.92e-05	0.000163	CcSEcCtD
Anagrelide—CYP1A2—Metapathway biotransformation—GSTM1—asthma	3.89e-05	0.0012	CbGpPWpGaD
Anagrelide—Musculoskeletal discomfort—Betamethasone—asthma	3.88e-05	0.000161	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Dexamethasone—asthma	3.88e-05	0.000161	CcSEcCtD
Anagrelide—Arthralgia—Prednisone—asthma	3.87e-05	0.000161	CcSEcCtD
Anagrelide—Myalgia—Prednisone—asthma	3.87e-05	0.000161	CcSEcCtD
Anagrelide—Feeling abnormal—Triamcinolone—asthma	3.87e-05	0.000161	CcSEcCtD
Anagrelide—Feeling abnormal—Methylprednisolone—asthma	3.86e-05	0.00016	CcSEcCtD
Anagrelide—Insomnia—Dexamethasone—asthma	3.85e-05	0.00016	CcSEcCtD
Anagrelide—Insomnia—Betamethasone—asthma	3.85e-05	0.00016	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—asthma	3.84e-05	0.00016	CcSEcCtD
Anagrelide—Gastrointestinal pain—Methylprednisolone—asthma	3.83e-05	0.000159	CcSEcCtD
Anagrelide—Paraesthesia—Betamethasone—asthma	3.82e-05	0.000159	CcSEcCtD
Anagrelide—Paraesthesia—Dexamethasone—asthma	3.82e-05	0.000159	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—CYBA—asthma	3.82e-05	0.00118	CbGpPWpGaD
Anagrelide—Discomfort—Prednisone—asthma	3.82e-05	0.000159	CcSEcCtD
Anagrelide—Dyspepsia—Betamethasone—asthma	3.75e-05	0.000156	CcSEcCtD
Anagrelide—Dyspepsia—Dexamethasone—asthma	3.75e-05	0.000156	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—PARP1—asthma	3.74e-05	0.00115	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IL5—asthma	3.74e-05	0.00115	CbGpPWpGaD
Anagrelide—Urticaria—Triamcinolone—asthma	3.73e-05	0.000155	CcSEcCtD
Anagrelide—Urticaria—Methylprednisolone—asthma	3.72e-05	0.000155	CcSEcCtD
Anagrelide—Body temperature increased—Triamcinolone—asthma	3.71e-05	0.000154	CcSEcCtD
Anagrelide—Oedema—Prednisone—asthma	3.71e-05	0.000154	CcSEcCtD
Anagrelide—Abdominal pain—Methylprednisolone—asthma	3.7e-05	0.000154	CcSEcCtD
Anagrelide—Decreased appetite—Dexamethasone—asthma	3.7e-05	0.000154	CcSEcCtD
Anagrelide—Decreased appetite—Betamethasone—asthma	3.7e-05	0.000154	CcSEcCtD
Anagrelide—Infection—Prednisone—asthma	3.68e-05	0.000153	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Dexamethasone—asthma	3.67e-05	0.000153	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Betamethasone—asthma	3.67e-05	0.000153	CcSEcCtD
Anagrelide—Fatigue—Betamethasone—asthma	3.67e-05	0.000153	CcSEcCtD
Anagrelide—Fatigue—Dexamethasone—asthma	3.67e-05	0.000153	CcSEcCtD
Anagrelide—Shock—Prednisone—asthma	3.65e-05	0.000152	CcSEcCtD
Anagrelide—Pain—Dexamethasone—asthma	3.64e-05	0.000151	CcSEcCtD
Anagrelide—Pain—Betamethasone—asthma	3.64e-05	0.000151	CcSEcCtD
Anagrelide—Nervous system disorder—Prednisone—asthma	3.64e-05	0.000151	CcSEcCtD
Anagrelide—Tachycardia—Prednisone—asthma	3.62e-05	0.00015	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—BDKRB2—asthma	3.61e-05	0.00111	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—POMC—asthma	3.6e-05	0.00111	CbGpPWpGaD
Anagrelide—Skin disorder—Prednisone—asthma	3.6e-05	0.00015	CcSEcCtD
Anagrelide—Hyperhidrosis—Prednisone—asthma	3.58e-05	0.000149	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—VEGFA—asthma	3.58e-05	0.0011	CbGpPWpGaD
Anagrelide—Asthenia—Hydrocortisone—asthma	3.57e-05	0.000149	CcSEcCtD
Anagrelide—Anorexia—Prednisone—asthma	3.53e-05	0.000147	CcSEcCtD
Anagrelide—Pruritus—Hydrocortisone—asthma	3.52e-05	0.000147	CcSEcCtD
Anagrelide—Feeling abnormal—Betamethasone—asthma	3.51e-05	0.000146	CcSEcCtD
Anagrelide—Feeling abnormal—Dexamethasone—asthma	3.51e-05	0.000146	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—ADCY2—asthma	3.49e-05	0.00108	CbGpPWpGaD
Anagrelide—Gastrointestinal pain—Dexamethasone—asthma	3.48e-05	0.000145	CcSEcCtD
Anagrelide—Gastrointestinal pain—Betamethasone—asthma	3.48e-05	0.000145	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—IL3—asthma	3.48e-05	0.00107	CbGpPWpGaD
Anagrelide—Diarrhoea—Hydrocortisone—asthma	3.41e-05	0.000142	CcSEcCtD
Anagrelide—Urticaria—Betamethasone—asthma	3.38e-05	0.000141	CcSEcCtD
Anagrelide—Urticaria—Dexamethasone—asthma	3.38e-05	0.000141	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Prednisone—asthma	3.38e-05	0.00014	CcSEcCtD
Anagrelide—Dizziness—Prednisolone—asthma	3.37e-05	0.00014	CcSEcCtD
Anagrelide—Asthenia—Triamcinolone—asthma	3.37e-05	0.00014	CcSEcCtD
Anagrelide—Body temperature increased—Dexamethasone—asthma	3.36e-05	0.00014	CcSEcCtD
Anagrelide—Body temperature increased—Betamethasone—asthma	3.36e-05	0.00014	CcSEcCtD
Anagrelide—Abdominal pain—Dexamethasone—asthma	3.36e-05	0.00014	CcSEcCtD
Anagrelide—Abdominal pain—Betamethasone—asthma	3.36e-05	0.00014	CcSEcCtD
Anagrelide—Asthenia—Methylprednisolone—asthma	3.36e-05	0.00014	CcSEcCtD
Anagrelide—Insomnia—Prednisone—asthma	3.35e-05	0.000139	CcSEcCtD
Anagrelide—Paraesthesia—Prednisone—asthma	3.33e-05	0.000138	CcSEcCtD
Anagrelide—Pruritus—Triamcinolone—asthma	3.32e-05	0.000138	CcSEcCtD
Anagrelide—Pruritus—Methylprednisolone—asthma	3.31e-05	0.000138	CcSEcCtD
Anagrelide—Dizziness—Hydrocortisone—asthma	3.29e-05	0.000137	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—TGFB1—asthma	3.29e-05	0.00101	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—KNG1—asthma	3.28e-05	0.00101	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—POMC—asthma	3.27e-05	0.00101	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AGTR1—asthma	3.26e-05	0.00101	CbGpPWpGaD
Anagrelide—Dyspepsia—Prednisone—asthma	3.26e-05	0.000136	CcSEcCtD
Anagrelide—Decreased appetite—Prednisone—asthma	3.22e-05	0.000134	CcSEcCtD
Anagrelide—Rash—Prednisolone—asthma	3.22e-05	0.000134	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ALOX15—asthma	3.22e-05	0.000991	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ALOX5AP—asthma	3.22e-05	0.000991	CbGpPWpGaD
Anagrelide—Dermatitis—Prednisolone—asthma	3.21e-05	0.000134	CcSEcCtD
Anagrelide—Diarrhoea—Methylprednisolone—asthma	3.2e-05	0.000133	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—CCL2—asthma	3.2e-05	0.000986	CbGpPWpGaD
Anagrelide—Fatigue—Prednisone—asthma	3.2e-05	0.000133	CcSEcCtD
Anagrelide—Headache—Prednisolone—asthma	3.2e-05	0.000133	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—IL6R—asthma	3.19e-05	0.000983	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CXCL10—asthma	3.19e-05	0.000983	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—RHOA—asthma	3.18e-05	0.000978	CbGpPWpGaD
Anagrelide—Constipation—Prednisone—asthma	3.17e-05	0.000132	CcSEcCtD
Anagrelide—Vomiting—Hydrocortisone—asthma	3.17e-05	0.000132	CcSEcCtD
Anagrelide—Rash—Hydrocortisone—asthma	3.14e-05	0.000131	CcSEcCtD
Anagrelide—Dermatitis—Hydrocortisone—asthma	3.14e-05	0.00013	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—NTRK1—asthma	3.13e-05	0.000964	CbGpPWpGaD
Anagrelide—Headache—Hydrocortisone—asthma	3.12e-05	0.00013	CcSEcCtD
Anagrelide—Dizziness—Triamcinolone—asthma	3.1e-05	0.000129	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—ADRB2—asthma	3.1e-05	0.000954	CbGpPWpGaD
Anagrelide—Dizziness—Methylprednisolone—asthma	3.1e-05	0.000129	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CHAT—asthma	3.07e-05	0.000945	CbGpPWpGaD
Anagrelide—Feeling abnormal—Prednisone—asthma	3.05e-05	0.000127	CcSEcCtD
Anagrelide—Asthenia—Betamethasone—asthma	3.05e-05	0.000127	CcSEcCtD
Anagrelide—Asthenia—Dexamethasone—asthma	3.05e-05	0.000127	CcSEcCtD
Anagrelide—Gastrointestinal pain—Prednisone—asthma	3.03e-05	0.000126	CcSEcCtD
Anagrelide—Nausea—Prednisolone—asthma	3.03e-05	0.000126	CcSEcCtD
Anagrelide—Pruritus—Dexamethasone—asthma	3.01e-05	0.000125	CcSEcCtD
Anagrelide—Pruritus—Betamethasone—asthma	3.01e-05	0.000125	CcSEcCtD
Anagrelide—Vomiting—Triamcinolone—asthma	2.98e-05	0.000124	CcSEcCtD
Anagrelide—Vomiting—Methylprednisolone—asthma	2.98e-05	0.000124	CcSEcCtD
Anagrelide—Nausea—Hydrocortisone—asthma	2.96e-05	0.000123	CcSEcCtD
Anagrelide—Rash—Triamcinolone—asthma	2.96e-05	0.000123	CcSEcCtD
Anagrelide—Dermatitis—Triamcinolone—asthma	2.96e-05	0.000123	CcSEcCtD
Anagrelide—Rash—Methylprednisolone—asthma	2.95e-05	0.000123	CcSEcCtD
Anagrelide—Dermatitis—Methylprednisolone—asthma	2.95e-05	0.000123	CcSEcCtD
Anagrelide—Urticaria—Prednisone—asthma	2.94e-05	0.000122	CcSEcCtD
Anagrelide—Headache—Triamcinolone—asthma	2.94e-05	0.000122	CcSEcCtD
Anagrelide—Headache—Methylprednisolone—asthma	2.93e-05	0.000122	CcSEcCtD
Anagrelide—Body temperature increased—Prednisone—asthma	2.93e-05	0.000122	CcSEcCtD
Anagrelide—Abdominal pain—Prednisone—asthma	2.93e-05	0.000122	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—ITPR1—asthma	2.93e-05	0.000902	CbGpPWpGaD
Anagrelide—Diarrhoea—Betamethasone—asthma	2.91e-05	0.000121	CcSEcCtD
Anagrelide—Diarrhoea—Dexamethasone—asthma	2.91e-05	0.000121	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—RHOA—asthma	2.88e-05	0.000888	CbGpPWpGaD
Anagrelide—Dizziness—Dexamethasone—asthma	2.81e-05	0.000117	CcSEcCtD
Anagrelide—Dizziness—Betamethasone—asthma	2.81e-05	0.000117	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—CD86—asthma	2.79e-05	0.000859	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—POMC—asthma	2.79e-05	0.000859	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—CXCL8—asthma	2.79e-05	0.000859	CbGpPWpGaD
Anagrelide—Nausea—Triamcinolone—asthma	2.79e-05	0.000116	CcSEcCtD
Anagrelide—Nausea—Methylprednisolone—asthma	2.78e-05	0.000116	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—EDN1—asthma	2.77e-05	0.000852	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCL5—asthma	2.75e-05	0.000846	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PLA2G4A—asthma	2.73e-05	0.000843	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ALOX5—asthma	2.73e-05	0.000842	CbGpPWpGaD
Anagrelide—Vomiting—Betamethasone—asthma	2.71e-05	0.000113	CcSEcCtD
Anagrelide—Vomiting—Dexamethasone—asthma	2.71e-05	0.000113	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—CSF2—asthma	2.7e-05	0.000833	CbGpPWpGaD
Anagrelide—Rash—Dexamethasone—asthma	2.68e-05	0.000112	CcSEcCtD
Anagrelide—Rash—Betamethasone—asthma	2.68e-05	0.000112	CcSEcCtD
Anagrelide—Dermatitis—Dexamethasone—asthma	2.68e-05	0.000111	CcSEcCtD
Anagrelide—Dermatitis—Betamethasone—asthma	2.68e-05	0.000111	CcSEcCtD
Anagrelide—Headache—Dexamethasone—asthma	2.67e-05	0.000111	CcSEcCtD
Anagrelide—Headache—Betamethasone—asthma	2.67e-05	0.000111	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—IL2—asthma	2.66e-05	0.000821	CbGpPWpGaD
Anagrelide—Asthenia—Prednisone—asthma	2.66e-05	0.000111	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—SMAD3—asthma	2.63e-05	0.000811	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—LTC4S—asthma	2.63e-05	0.00081	CbGpPWpGaD
Anagrelide—Pruritus—Prednisone—asthma	2.62e-05	0.000109	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—asthma	2.61e-05	0.000803	CbGpPWpGaD
Anagrelide—Diarrhoea—Prednisone—asthma	2.54e-05	0.000105	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—CXCL8—asthma	2.53e-05	0.00078	CbGpPWpGaD
Anagrelide—Nausea—Betamethasone—asthma	2.53e-05	0.000105	CcSEcCtD
Anagrelide—Nausea—Dexamethasone—asthma	2.53e-05	0.000105	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—PPP2CA—asthma	2.52e-05	0.000776	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCR5—asthma	2.47e-05	0.000762	CbGpPWpGaD
Anagrelide—Dizziness—Prednisone—asthma	2.45e-05	0.000102	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—IL2RA—asthma	2.44e-05	0.000751	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—IL2—asthma	2.42e-05	0.000745	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—C3—asthma	2.42e-05	0.000745	CbGpPWpGaD
Anagrelide—Vomiting—Prednisone—asthma	2.36e-05	9.8e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—PDGFB—asthma	2.35e-05	0.000725	CbGpPWpGaD
Anagrelide—Rash—Prednisone—asthma	2.34e-05	9.72e-05	CcSEcCtD
Anagrelide—Dermatitis—Prednisone—asthma	2.34e-05	9.71e-05	CcSEcCtD
Anagrelide—Headache—Prednisone—asthma	2.32e-05	9.66e-05	CcSEcCtD
Anagrelide—CYP1A2—Metabolism—LTA4H—asthma	2.28e-05	0.000702	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—LEP—asthma	2.25e-05	0.000693	CbGpPWpGaD
Anagrelide—Nausea—Prednisone—asthma	2.2e-05	9.15e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—FN1—asthma	2.12e-05	0.000654	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ARG1—asthma	1.99e-05	0.000614	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—POMC—asthma	1.93e-05	0.000596	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCL2—asthma	1.89e-05	0.000583	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IL6R—asthma	1.89e-05	0.000581	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—EGFR—asthma	1.85e-05	0.00057	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALDH7A1—asthma	1.8e-05	0.000555	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SERPINE1—asthma	1.77e-05	0.000544	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ARG2—asthma	1.73e-05	0.000532	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—RHOA—asthma	1.7e-05	0.000525	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NOS3—asthma	1.69e-05	0.000519	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—asthma	1.51e-05	0.000467	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CXCL8—asthma	1.5e-05	0.000461	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALOX5AP—asthma	1.43e-05	0.000441	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALOX15—asthma	1.43e-05	0.000441	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IL2—asthma	1.43e-05	0.00044	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—IL6—asthma	1.42e-05	0.000438	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CHAT—asthma	1.37e-05	0.000421	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MMP9—asthma	1.35e-05	0.000417	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PTEN—asthma	1.34e-05	0.000414	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALOX5—asthma	1.22e-05	0.000375	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—VEGFA—asthma	1.21e-05	0.000374	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—STAT3—asthma	1.2e-05	0.00037	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CARM1—asthma	1.16e-05	0.000358	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—DCN—asthma	1.14e-05	0.000353	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TGFB1—asthma	1.11e-05	0.000343	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALDH2—asthma	1.11e-05	0.000343	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—EGFR—asthma	1.09e-05	0.000337	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—POMC—asthma	1.07e-05	0.00033	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTT1—asthma	1.06e-05	0.000326	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—asthma	9.76e-06	0.000301	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NQO1—asthma	8.8e-06	0.000271	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ADCY2—asthma	8.61e-06	0.000265	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—asthma	8.54e-06	0.000263	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IL6—asthma	8.4e-06	0.000259	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—asthma	7.45e-06	0.000229	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTP1—asthma	7.34e-06	0.000226	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HMOX1—asthma	7.24e-06	0.000223	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ITPR1—asthma	7.22e-06	0.000223	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CAT—asthma	7.14e-06	0.00022	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTM1—asthma	6.75e-06	0.000208	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PLA2G4A—asthma	6.75e-06	0.000208	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PPP2CA—asthma	6.21e-06	0.000191	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—POMC—asthma	4.77e-06	0.000147	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALB—asthma	4.35e-06	0.000134	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NOS3—asthma	4.16e-06	0.000128	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PTGS2—asthma	3.8e-06	0.000117	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PTEN—asthma	3.32e-06	0.000102	CbGpPWpGaD
